PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
Phase 3
Completed
- Conditions
- Neuralgia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 276
- Registration Number
- NCT00150436
Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 147
- Registration Number
- NCT00150345
- Locations
- 🇩🇪
Pfizer Investigational Site, Wuerzburg, Germany
A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT00150397
- Locations
- 🇮🇳
Pfizer Investigational Site, Noida, Uttar Pradesh, India
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Phase 3
Completed
- Conditions
- Infections, Nosocomial
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00150332
- Locations
- 🇯🇵
Pfizer Investigational Site, Okayama, Japan
A First In Human Study Of PF-00184562 In Healthy Volunteers
Phase 1
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00150215
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
Phase 3
Completed
- Conditions
- Anxiety Neuroses
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 511
- Registration Number
- NCT00150449
- Locations
Pfizer Investigational Site
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
Phase 3
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 976
- Registration Number
- NCT00150267
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 626
- Registration Number
- NCT00150410
- Locations
- 🇲🇽
Pfizer Investigational Site, Mexico Df, Mexico
An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend
Phase 1
Terminated
- Conditions
- Kidney Failure
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT00150319
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT00150254
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath